| Popis: |
© 2016, Springer Science+Business Media New York.Though normally bone regenerates well, non-union, delayed union, or defective bone formation can occur. Since impaired healing is often caused by local trophic disorders, standard fracture management is often ineffective. Gene therapy is a promising field for bone engineering. We have created a recombinant plasmid construct encoding the genes for pro-angiogenic vascular endothelial growth factor 165A (VEGF165A) and pro-osteogenic bone morphogenetic protein 2 (BMP2) with kanamycin resistance (pBudKan-VEGF165A-BMP2). This plasmid has the potential for use in treatment of trauma and skeletal system disorders, especially in cases of low trophicity. |
